Lapas attēli
PDF
ePub

(2) Shall include the statement for class I exempt ASR's: “Analyte Specific Reagent. Analytical and performance characteristics are not established";

(3) Shall include the statement for class II or III ASR's: “Analyte Specific Reagent. Except as a component of the approved/cleared test (name of approved/cleared test), analytical and performance characteristics are not established”; and

(4) Shall not make any statement regarding analytical or clinical performance.

(e) The laboratory that develops an in-house test using the ASR shall inform the ordering person of the test result by appending to the test report the statement: "This test was developed and its performance characteristics determined by (Laboratory Name). It has not been cleared or approved by the U.S. Food and Drug Administration." This statement would not be applicable or required when test results are generated using the test that was cleared or approved in conjunction with review of the class II or III ASR.

(1) Ordering in-house tests that are developed using analyte specific reagents is limited under section 520(e) of the act to physicians and other persons authorized by applicable State law to order such tests.

(g) The restrictions in paragraphs (c) through (f) of this section do not apply when reagents that otherwise meet the analyte specific reagent definition are sold to:

(1) In vitro diagnostic manufacturers; or

(2) Organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other nonclinical laboratories.

520(e) of the Act subject to the restrictions set forth in this section.

(b) Sample testing shall be performed in a laboratory using screening tests that have been approved, cleared, or otherwise recognized by the Food and Drug Administration as accurate and reliable for the testing of such specimens for identifying drugs of abuse or their metabolites.

(c) The laboratory performing the test(s) shall have, and shall be recognized as having, adequate capability to reliably perform the necessary screening and confirmatory tests, including adequate capability to perform integrity checks of the biological specimens for possible adulteration.

(d) All OTC test sample collection systems for drugs of abuse testing shall be labeled in accordance with $ 809.10(1) and shall provide an adequate system to communicate the proper interpretation of test results from the laboratory to the lay purchaser. [65 FR 18234, Apr. 7, 2000)

EFFECTIVE DATE NOTE: At 65 FR 18234, Apr. 7, 2000, $ 809.40 was added to subpart C of part 809, effective Apr. 9, 2001. At 66 FR 17359, Mar. 30, 2001, the effective date was delayed until June 8, 2001.

PART 810-MEDICAL DEVICE

RECALL AUTHORITY

Subpart A-General Provisions

Sec. 810.1 Scope. 810.2 Definitions. 810.3 Computation of time. 810.4 Service of orders.

[62 FR 62259, Nov. 21, 1997]

Subpart B-Mandatory Medical Device

Recall Procedures 810.10 Cease distribution and notification

order. 810.11 Regulatory hearing. 810.12 Written request for review of cease

distribution and notification order. 810.13 Mandatory recall order. 810.14 Cease distribution and notification or

mandatory recall strategy. 810.15 Communications concerning a cease

distribution and notification or manda

tory recall order. 810.16 Cease distribution and notification or

mandatory recall order status reports. 810.17 Termination of a cease distribution

and notification or mandatory recall order.

$ 809.40 Restrictions on the sale, dis

tribution, and use of OTC test sam. ple collection systems for drugs of

abuse testing. (a) Over-the-counter (OTC) test sample collection systems for drugs of abuse testing (8 864.3260 of this chapter) are restricted devices under section

810.18 Public notice.

(h) Reasonable probability means that AUTHORITY: 21 U.S.C. 321, 331, 332, 333, 334,

it is more likely than not that an event 351, 352, 360h, 371, 374, 375.

will occur.

(i) Serious, adverse health consequence SOURCE: 61 FR 59018, Nov. 20, 1996, unless

means any significant adverse experiotherwise noted.

ence, including those that may be ei

ther life-threatening or involve permaSubpart A-General Provisions

nent or long-term injuries, but exclud

ing injuries that are nonlife-threat8810.1 Scope.

ening and that are temporary and reaPart 810 describes the procedures sonably reversible. that the Food and Drug Administra- (j) Recall means the correction or retion will follow in exercising its med- moval of a device for human use where ical device recall authority under sec- FDA finds that there is a reasonable tion 518(e) of the Federal Food, Drug, probability that the device would cause and Cosmetic Act.

serious, adverse health consequences or

death. $ 810.2 Definitions.

(k) Removal means the physical reAs used in this part:

moval of a device from its point of use (a) Act means the Federal Food,

to some other location for repair, Drug, and Cosmetic Act.

modification, adjustment, relabeling, (b) Agency or FDA means the Food

destruction, or inspection. and Drug Administration.

$810.3 Computation of time. (c) Cease distribution and notification strategy or mandatory recall strategy

In computing any period of time premeans a planned, specific course of ac

scribed or allowed by this part, the day tion to be taken by the person named

of the act or event from which the desin a cease distribution and notification

ignated period of time begins to run order or in a mandatory recall order,

shall not be included. The computation which addresses the extent of the noti

of time is based only on working days. fication or recall, the need for public

8810.4 Service of orders. warnings, and the extent of effectiveness checks to be conducted.

Orders issued under this part will be (d) Consignee means any person or

served in person by a designated emfirm that has received, purchased, or

ployee of FDA, or by certified or regused a device that is subject to a cease istered mail or similar mail delivery distribution and notification order or a service with a return receipt record remandatory recall order. Consignee does

flecting receipt, to the named person or not mean lay individuals or patients, designated agent at the named person's i.e., nonhealth professionals.

or designated agent's last known ad(e) Correction means repair, modifica

dress in FDA's records. tion, adjustment, relabeling, destruction, or inspection (including patient Subpart B-Mandatory Medical monitoring) of a device, without its Device Recall Procedures physical removal from its point of use to some other location.

8810.10 Cease distribution and notifi

cation order. (f) Device user facility means a hospital, ambulatory surgical facility, (a) If, after providing the appropriate nursing home, or outpatient treatment person with an opportunity to consult or diagnostic facility that is not a phy- with the agency, FDA finds that there sician's office.

is a reasonable probability that a de(g) Health professionals means practi- vice intended for human use would tioners, including physicians, nurses, cause serious, adverse health conpharmacists, dentists, respiratory sequences or death, the agency may therapists, physical therapists, tech- issue a cease distribution and notificanologists, or any other practitioners or tion order requiring the person named allied health professionals that have a in the order to immediately: role in using a device for human use. (1) Cease distribution of the device;

(4) The total number of units of the device estimated to be in the hands of home users;

(5) Distribution information, including the names and addresses of all consignees;

(6) A copy of any written communication used by the person named in the order to notify health professionals and device user facilities;

(7) A proposed strategy for complying with the cease distribution and notification order;

(8) Progress reports to be made at specified intervals, showing the names and addresses of health professionals and device user facilities that have been notified, names of specific individuals contacted within device user facilities, and the dates of such contacts; and

(9) The name, address, and telephone number of the person who should be contacted concerning implementation of the order.

(e) FDA will provide the person named in a cease distribution and notification order with an opportunity for a regulatory hearing on the actions required by the cease distribution and notification order and on whether the order should be modified, or vacated, or amended to require a mandatory recall of the device.

(f) FDA will also provide the person named in the cease distribution and notification order with an opportunity, in lieu of a regulatory hearing, to submit a written request to FDA asking that the order be modified, or vacated, or amended.

(g) FDA will include in the cease distribution and notification order the name, address, and telephone number of an agency employee to whom any request for a regulatory hearing or agency review is to be addressed.

cause

(2) Notify health professionals and device user facilities of the order; and

(3) Instruct these professionals and device user facilities to cease use of the device.

(b) FDA will include the following information in the order:

(1) The requirements of the order relating to cessation of distribution and notification of health professionals and device user facilities;

(2) Pertinent descriptive information to enable accurate and immediate identification of the device subject to the order, including, where known:

(i) The brand name of the device;

(ii) The common name, classification name, or usual name of the device;

(iii) The model, catalog, or product code numbers of the device; and

(iv) The manufacturing lot numbers or serial numbers of the device or other identification numbers; and

(3) A statement of the grounds for FDA's finding that there is a reasonable probability that the device would

serious, adverse health sequences or death.

(C) FDA may also include in the order a model letter for notifying health professionals and device user facilities of the order and a requirement that notification of health professionals and device user facilities be completed within a specified timeframe. The model letter will include the key elements of information that the agency in its discretion has determined, based on the circumstances surrounding the issuance of each order, are necessary to inform health professionals and device user facilities about the order.

(d) FDA may also require that the person named in the cease distribution and notification order submit any or all of the following information to the agency by a time specified in the order:

(1) The total number of units of the device produced and the timespan of the production;

(2) The total number of units of the device estimated to be in distribution channels;

(3) The total number of units of the device estimated to be distributed to health professionals and device user facilities;

con

8810.11 Regulatory hearing.

(a) Any request for a regulatory hearing shall be submitted in writing to the agency employee identified in the order within the timeframe specified by FDA. Under $ 16.22(b) of this chapter, this timeframe ordinarily will not be fewer than 3 working days after receipt of the cease distribution and notification order. However, as provided in $16.60(h) of this chapter, the Commissioner of Food and Drugs or presiding officer may waive, suspend, or modify any provision of part 16 under $10.19 of this chapter, including those pertaining to the timing of the hearing. As provided in $16.26(a), the Commissioner or presiding officer may deny a request for a hearing, in whole or in part, if he or she determines that no genuine and substantial issue of fact is raised by the material submitted in the request.

(b) If a request for a regulatory hearing is granted, the regulatory hearing shall be limited to:

(1) Reviewing the actions required by the cease distribution and notification order, determining if FDA should affirm, modify, or vacate the order, and addressing an appropriate cease distribution and notification strategy; and

(2) Determining whether FDA should amend the cease distribution and notification order to require a recall of the device that was the subject of the order. The hearing may also address the actions that might be required by a recall order, including an appropriate recall strategy, if FDA later orders a recall.

(c) If a request by the person named in a cease distribution and notification order for a regulatory hearing is granted, the regulatory hearing will be conducted in accordance with the procedures set out in section 201(x) of the act (21 U.S.C. 321(x)) and part 16 of this chapter, except that the order issued under $810.10, rather than a notice under $16.22(a) of this chapter, provides the notice of opportunity for a hearing and is part of the administrative record of the regulatory hearing under $ 16.80(a) of this chapter. As provided in $16.60(h) of this chapter, the Commissioner of Food and Drugs or presiding officer may waive, suspend, or modify any provision of part 16 under $10.19 of this chapter. As provided in $16.26(b), after the hearing commences, the presiding officer may issue a summary decision on any issue if the presiding officer determines that there is no genuine and substantial issue of fact respecting that issue.

(d) If the person named in the cease distribution and notification order does

not request a regulatory hearing within the timeframe specified by FDA in the cease distribution and notification order, that person will be deemed to have waived his or her right to request a hearing.

(e) The presiding officer will ordinarily hold any regulatory hearing requested under paragraph (a) of this section no fewer than 2 working days after receipt of the request for a hearing, under $16.24(e) of this chapter, and no later than 10 working days after the date of issuance of the cease distribution and notification order. However, FDA and the person named in the order may agree to a later date or the presiding officer may determine that the hearing should be held in fewer than 2 days. Moreover, as provided for in $16.60(h) of this chapter, the Commissioner of Food and Drugs or presiding officer may waive, suspend, or modify any provision of part 16 under $10.19 of this chapter, including those pertaining to the timing of the hearing. After the presiding officer prepares a written report of the hearing and the agency issues a final decision based on the report, the presiding officer shall provide the requestor written notification of the final decision to affirm, modify, or vacate the order or to amend the order to require a recall of the device within 15 working days of conducting a regulatory hearing.

$ 810.12 Written request for review of

cease distribution and notification

order. (a) In lieu of requesting a regulatory hearing under $810.11, the person named in a cease distribution and notification order may submit a written request to FDA asking that the order be modified or vacated. Such person shall address the written request to the agency employee identified in the order and shall submit the request within the timeframe specified in the order, unless FDA and the person named in the order agree to a later date.

(b) A written request for review of a cease distribution and notification order shall identify each ground upon which the requestor relies in asking that the order be modified or vacated, as well as addressing an appropriate cease distribution and notification strategy, and shall address whether the order should be amended to require a recall of the device that was the subject of the order and the actions required by such a recall order, including an appropriate recall strategy.

(c) The agency official who issued the cease distribution and notification order shall provide the requestor written notification of the agency's decision to affirm, modify, or vacate the order or amend the order to require a recall of the device within 15 working days of receipt of the written request. The agency official shall include in this written notification:

(1) A statement of the grounds for the decision to affirm, modify, vacate, or amend the order; and

(2) The requirements of any modified or amended order.

(2) Specify a timetable in accordance with which the recall is to begin and be completed;

(3) Require the person named in the order to submit to the agency a proposed recall strategy, as described in 8810.14, and periodic reports describing the progress of the mandatory recall, as described in $810.16; and

(4) Provide the person named in the order with a model recall notification letter that includes the key elements of information that FDA has determined are necessary to inform health professionals and device user facilities.

(C) FDA will not include in a mandatory recall order a requirement for:

(1) Recall of a device from individuals; or

(2) Recall of a device from device user facilities, if FDA determines that the risk of recalling the device from the facilities presents a greater health risk than the health risk of not recalling the device from use, unless the device can be replaced immediately with an equivalent device.

(d) FDA will include in a mandatory recall order provisions for notification to individuals subject to the risks associated with use of the device. If a significant number of such individuals cannot be identified, FDA may notify such individuals under section 705(b) of the act.

8 810.13 Mandatory recall order.

(a) If the person named in a cease distribution and notification order does not request a regulatory hearing or submit a request for agency review of the order, or, if the Commissioner of Food and Drugs or the presiding officer denies a request for a hearing, or, if after conducting a regulatory hearing under $810.11 or completing agency review of a cease distribution and notification order under $810.12, FDA determines that the order should be amended to require a recall of the device with respect to which the order was issued, FDA shall amend the order to require such a recall. FDA shall amend the order to require such a recall within 15 working days of issuance of a cease distribution and notification order if a regulatory hearing or agency review of the order is not requested, or within 15 working days of denying a request for a hearing, or within 15 working days of completing a regulatory hearing under 8810.11, or within 15 working days of receipt of a written request for review of a cease distribution and notification order under $810.12.

(b) In a mandatory recall order, FDA may:

(1) Specify that the recall is to extend to the wholesale, retail, or user level;

$810.14 Cease distribution and notifi.

cation or mandatory recall strategy. (a) General. The person named in a cease distribution and notification order issued under $810.10 shall comply with the order, which FDA will fashion as appropriate for the individual circumstances of the case. The person named in a cease distribution and notification order modified under $810.11(e) or $810.12(c) or a mandatory recall order issued under $810.13 shall develop a strategy for complying with the order that is appropriate for the individual circumstances and that takes into account the following factors:

(1) The nature of the serious, adverse health consequences related to the device;

(2) The ease of identifying the device;

(3) The extent to which the risk presented by the device is obvious to a

« iepriekšējāTurpināt »